GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Author's Avatar
Dec 12, 2022

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced results from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemia (AML). These results were presented at the 64th American Society of Hematology (ASH) Annual Meeting.